Condition: Obsessive-Compulsive Disorder · Anxiety Disorders · Major Depressive Disorder · Sponsor: University of Calgary
The purpose of this study is to identify pharmacogenetic profiles associated with selective serotonin reuptake inhibitors (SSRI)-induced behavioral disinhibition in children with Major depressive disorder (MDD), anxiety disorders and/or obsessive-compulsive disorder (OCD) that could be used clinically to reduce the incidence of this adverse event and improve health outcomes.
This description comes directly from the study's public registry record.
Madison Heintz, MSW · 5875739747 · psychpgxlab@ucalgary.ca
Abdullah Al Maruf, PhD · abdullahal.maruf@ucalgary.ca
Always discuss trial participation with your own doctor first.
| Child and Adolescent Addiction, Mental Health & Psychiatry | Calgary, Alberta, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03953014